Introduction
Hemophilia A is characterized by a deficiency or protein abnormality in factor VIII resulting in recurrent bleeding episodes, most commonly in joints. Hemarthrosis may lead to pain, muscular atrophy, arthropathy and joint deformities.
1 Individuals with joint damage may have limited mobility; while those without joint damage may limit their activities to minimize their risk of bleeding. 2 In addition to the physical impairments, hemophilia can impact a patient's psychological, social, and economic well-being.
Standard of care of patients with severe hemophilia is intravenous replacement of FVIII either through episodic ("on demand") treatment given at the time of bleeding or other hemostatic challenges or prophylactic treatment which involves several injections per week to prevent bleeding. The half-life of standard recombinant FVIII (rFVIII) products is 10-12 hours. 1, 5 More recently, extended half-life (EHL) factor concentrates have been developed which can potentially benefit patients by extending the duration of protection from bleeding, reducing the number of injections and/or increasing the patient's trough factor level which could reduce bleeding. 5, 6 Prophylactic treatment regimens have led to improvements in health-related quality-of-life (HRQoL) among individuals with hemophilia. [7] [8] [9] [10] Turoctocog alfa pegol (N8-GP, Novo Nordisk, Bagsvaerd, Denmark), an EHL glycoPEGylated rFVIII product, was developed for the prevention and treatment of bleeds in hemophilia A patients. N8-GP was previously demonstrated to result in a 1.6-fold prolongation of mean terminal half-life. 11 Given the potential advantages of EHL factor concentrates, it is hypothesized that N8-GP may result in further improvement in HRQoL for hemophilia A patients. The safety and efficacy of N8-GP have been evaluated in children, adolescents, and adults with severe hemophilia A in two multinational clinical phase III trials (pathfinder™5 and pathfinder™2). 12, 13 In the pathfinder™5 trial, the median annualized bleeding rate (ABR) was 1.95, with 42.6% (n=29) of the subjects reporting no bleeds while on N8-GP prophylaxis. 12 In the pathfinder™2 trial, the median ABR was 1.18 among those on N8-GP prophylaxis, with 40% (n=70) reporting no bleeds. 13 Both trials demonstrated that N8-GP had a favorable safety profile and was effective in preventing bleeds in patients with severe hemophilia A. 12, 13 HRQoL was a secondary endpoint in both trials. It was hypothesized that there would be improvements in patients' HRQoL and increased treatment satisfaction (TS), as N8-GP extends the duration of coverage, which results in less bleeds, and requires fewer injections. The changes in HRQoL and TS in individuals with hemophilia A who received N8-GP within these trials are presented in this article.
Materials and methods study design and patient population
Pathfinder™5 (NCT01731600) was a phase III, multicenter, multinational, open-label single-arm trial. Patients enrolled in pathfinder™5 were ,12 years of age, with severe hemophilia A (,1 % FVIII), had no history of inhibitors, and had been previously treated with FVIII products. Subjects in pathfinder™5 were followed for 26 weeks and received a fixed dose of N8-GP via intravenous injection twice weekly. A total of 68 patients were included in pathfinder™5; 20 were aged #4 years, 23 were aged 4-7 years, and 25 were aged 8-11 years.
Pathfinder™2 (NCT01480180) was a phase III, multicenter, multinational, open-label, non-randomized trial. Patients enrolled in pathfinder™2 were $12 years of age with severe hemophilia A (,1 % FVIII), had no history of inhibitors and had been previously treated with FVIII products. Patients were allocated to either the on-demand treatment arm (exposure days [ED]; Mean=55.2 [SD=35.6], range=14-146 days) or prophylaxis treatment arm (every 4 days) of N8-GP at the discretion of the investigator, and were followed between 6 and 27 months. A total of 186 patients were included in pathfinder™2; two were aged 12 years, 16 were aged 13-16 years, and 168 were adults aged $17 years.
Both trials were approved by relevant independent ethics committees, institutional review boards, regulatory authorities, and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients (adults or children who are able to provide consent) or their legally authorized representatives (children who are unable to provide consent) provided written informed consent before any trial-related activities. Both trials consisted of a main phase and an extension phase. As the extension phase is still ongoing, only the results of the main phase are reported here. The questionnaires were completed at two timepoints: prior to treatment with N8-GP and at the end of the main phase of each of the trials (pathfinder™5 at 26 weeks and pathfinder™2 at 76 weeks).
Patient-reported outcomes (PrO) and observer-reported outcomes (ObsrO) questionnaires
The Haemo-QoL and Haem-A-QoL are disease-specific HRQoL tools that have been validated in hemophilia patients of different ages. 14, 15 The Haemo-QoL I (ages 4-7 years) consists of 21 items covering eight domains; the Haemo-QoL II (ages 8-12 years) consists of 64 items covering 10 domains, and the Haemo-QoL III (13-16 years) consists of 77 items covering 12 domains. For each age group version, there is a child and a parent proxy version available. The Haem-A-QoL (used in patients ages $17 years) consists of 46 items covering 10 domains. A total score and domain scores range from 0-100, with lower scores indicating a better hemophiliarelated QoL. Domain and content for each version of the The Hemo-Sat A consists of 34 items covering six domains. The Hemo-Sat P measures the satisfaction with their child's treatment and includes the same items and domains as the Hemo-Sat A , but with one additional item in the "ease and convenience" domain. Each domain score ranges from 0-100, with lower scores indicating a higher level of hemophilia TS.
statistical analysis
Each trial was analyzed separately. Within each trial, the analyses were separated by age groups according to the recommended age of the respective questionnaire version. In pathfinder™2, two patients were excluded from the analyses, as they took the Haemo-QoL II at baseline (aged 12) and the Haemo-QoL III (age 13) at the end of the main phase, thus a change in score could not be computed for these patients. Therefore, these patients were excluded from our analyses. Patients in pathfinder™2 who started the trial with ondemand treatment, but switched to prophylaxis treatment, were included in both treatment groups in the demographic characteristics analyses and only included in the prophylaxis group for the HRQoL and TS analyses. Descriptive statistics were applied to examine the change in PRO and ObsRO scores from baseline to the end of the main phase of the trials. Responder analyses were performed using previously defined Haemo-QoL/Haem-A-QoL responder thresholds that were developed using a distribution-based method. 18 Within the adult group of pathfinder™2, the analyses were also performed according to treatment arm (on demand and prophylaxis), with a non-parametric signed-rank test to compare the change from baseline to end of main phase of the trial with a statistical significance threshold set at 5%. Categorical values were presented as absolute and relative frequencies, while continuous variables were presented as means (standard deviations). All data processing and analyses were performed using SAS software for Windows version 9.4 (SAS Institute, Inc., Cary, NC, USA). Table 1 presents the description of patient characteristics at baseline, and Table 2 presents the completion rate of each PRO/ObsRO questionnaire in both trials. Not all patients completed the PRO questionnaires at baseline, and some patients did not fill in the questionnaires at the end of the main phase resulting in a lower number of patients for whom HRQoL data were available at both baseline and end of main phase. Change in Haemo-QoL/Haem-A-QoL scores could be computed for seven children (30.4%) and 14 parents (60.9%) out of 23 children in age group 4-7 years, 21 out One patient changed treatment regimen from on-demand to prophylaxis at Visit 6. Therefore, he is included in both the prophylaxis and on-demand arm, but only counted once in the total.
Results

study population
b europe included croatia, Denmark, France, germany, greece, hungary, italy, lithuania, the netherlands, norway, Portugal, russia, spain, sweden, switzerland, Ukraine, and the UK. 
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Kearney et al of 25 children and parents (84%) in age group 8-11 years; from all enrolled patients in pathfinder™2 change in Haemo-QoL/Haem-A-QoL scores could be computed for 10 adolescents (62.5%) and nine parents (56.3%) out of 16 in the age group 13-16 years and 163 out of 168 adults (97.0%). Change in Hemo-Sat P scores could be computed for 54 parents of patients (79.4%) across all age groups in pathfinder™5, and four parents of patients (40%) of 13-16 years in pathfinder™2. Change in Hemo-Sat A scores could be computed for 162 of 168 (96.4%) adults in pathfinder™2. All pediatric patients in pathfinder™5 and all the adolescents aged 13-16 years in pathfinder™2 were on prophylaxis during the trial. Among the adults, 11 received on-demand treatment and 157 received prophylaxis in pathfinder™2, including one patient who switched from on-demand treatment to prophylaxis treatment at visit 6.
HRQoL in pathfinder™2
As shown in Table 3 , baseline "total Haemo-QoL III" scores in the 13-16 year age group were low, indicating a good overall hemophilia-specific HRQoL, according to both the adolescents and their parents. Adolescents also reported low domain scores for across each domain at baseline, with the exception of "Perceived Support". Mean change in "total Haemo-QoL" scores yielded no change in HRQoL according to the adolescents and their parents. Adolescents had no changes in any domain, while parents reported improvements in "Others" and "Physical Health" domains and declines in "Perceived Support" and "Friend" domains. According to the "total Haemo-QoL III" responder threshold, 18 overall HRQoL improvement was observed for 12.5% of adolescents and 18.8% of their parents. As shown in Table 4 , adults in the prophylaxis arm had a lower "total Haem-A-QoL" score at baseline when compared to adults in the on-demand arm. Moderate baseline Haem-A-QoL scores were observed in the "Physical Health", "Feeling", "View", "Sport", and "Future" domains for the on-demand arm and "Sport" domain for the prophylaxis arm. There were no significant differences in change in scores between the two treatment arms. For the on-demand arm, there were no significant within group changes for any of the Haem-A-QoL scores. However, most scores trended towards improvement (negative change in scores). Within the prophylaxis arm, there were statistically significant improvements for the "Physical Health" (P,0.001), "Work" (P=0.003), "Feeling" (P=0.016), and "View" (P=0.048) domains and the "total HAEM-A-QOL" score (P=0.002). In total, 54.5% of adults in the on-demand arm and 24.2% of adults in the prophylaxis arm improved in HRQoL according to the "total Haem-A-QoL" responder threshold. 18 
HRQoL in pathfinder™5
As shown in Table 3 , children and their parents in the 4-7 year age group reported a relatively good overall hemophilia-specific HRQoL at baseline, based on the mean "total Haemo-QoL I" scores. Most of the baseline Haemo-QoL I domain scores were also on the lower end of the scale (indicative of a good HRQoL), except for "Family" according to both the children and their parents, "Treatment" according to the children, and "Preschool/ a some patients had a missing baseline score or end of main phase score, therefore a change in score was not able to be computed for these patients. Two patients who were 12 years old in pathfinder™ 2 were excluded from the analyses as they completed the Haemo-QoL II at baseline and Haemo-QoL III at the end of the main phase and a change of score cannot be computed. The Hemo-Sat questionnaire is an instrument designed specifically to assess TS in patients with hemophilia. The Hemo-Sat A consists of 34 items covering six domains. The hemo-sat P (a version for parents of children with hemophilia who are aged ,17 years) it measures the satisfaction with their child's treatment and includes the same items and domains as the hemo-sat A , but with one additional item in the "ease and con venience" domain. School" according to the parents. Mean "total Haemo-QoL I" change score demonstrated a marked improvement (mean score exceeding a previously defined responder threshold) 18 in HRQoL as reported by the children and their parents. Children showed marked improvements in "Family", "Feeling", and "Physical Health" domains; while parents reported marked improvements in "Others", "Physical Health", and "Family" domains. According to the "total Haemo-QoL I" responder threshold, 18 overall HRQoL improvement was observed for 17% of children and 30% of their parents.
In the 8-11 year age group, children and their parents reported a relatively good overall hemophilia-specific HRQoL at baseline (Table 3 ). There were low mean domain scores at baseline for all domains except for the "Friend" domain according to the parents. Mean change for the "total HaemoQoL II" score demonstrated minimal change in HRQoL as reported by the children, and marked improvement in HRQoL by their parents. Children showed marked improvements in the "Physical Health" domain; while trending towards improvements in other domains. A modest decline was found in their relationship with their "Friends" relating to hemophilia. 
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Kearney et al Both children and their parents had a modest decline in the "Perceived support" domain. Parents reported marked improvements in the "View", "Physical Health", "Family", and "Feeling" domains; while trending towards improvements in other domains. When applying the "total Haemo-QoL II" score responder threshold, 18 44.0% of children and 56.0% of parents have reported improvements in overall HRQoL.
Treatment satisfaction
Figures 1 and 2 present the mean Hemo-Sat P scores of parents in pathfinder™5 and pathfinder™2, respectively, at baseline and the end of the main phase, and show the mean change (∆Hemo-Sat P ) in parents who completed the Hemo-Sat P at both baseline and the end of the main phase.
Parents reported high levels of TS at baseline visits in both trials, which indicates that they had a high level of TS with the treatment received prior to entering the trial. At the end of the main phase visits, mean Hemo-Sat P scores were also low for all age groups in both trials, indicating high levels of TS with N8-GP. The mean change in Hemo-Sat P scores indicated that parents had higher satisfaction or a similar level of satisfaction with N8-GP as compared to the treatment received prior to entering the trial. Figure 3 presents the mean baseline, end-of-treatment, and change Hemo-Sat A scores of adults in pathfinder™2 treated on-demand, and Figure 4 presents the mean baseline, endof-treatment, and change Hemo-Sat A scores of adults treated prophylactically. Similar to the parents, adults reported high a some patients had a missing baseline score or end of main phase score, therefore a change in score was not able to be computed for these patients; a negative change in score implies an improvement in hrQol. P-values indicate significance within change using the signed-rank test: *P,0.05, **P,0.0001. Abbreviation: hrQol, health-related quality-of-life.
BL (N=61)
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Kearney et al levels of satisfaction at the baseline visits and at the end of the main phase visits. For adults, the level of satisfaction between those in the on-demand arm and those in the prophylaxis arm were comparable. When examining the change in Hemo-Sat A scores, mean changes in all domains indicated that TS was either comparable or higher with N8-GP compared to the treatment received prior to entering the pathfinder™ trial.
Discussion
The objective of the analysis reported in this article was to investigate the HRQoL and treatment satisfaction of children, adolescents, and adults with severe hemophilia A treated with N8-GP in the pathfinder™5 and pathfinder™2 trials using disease-specific, age-appropriate, validated questionnaires. 15, 16 At baseline, all patients across trials reported a good overall HRQoL as indicated by their total Haemo-QoL/ Haem-A-QoL scores. Thus, there was generally little room for improvement for any group. Improvement in "Physical Health" and overall hemophilia-specific HRQoL was observed in pediatric patients aged 4-7 and 8-11 and adults $17 years treated with N8-GP prophylaxis during the trials. The adolescents aged 13-16 years reported that their hemophilia-specific HRQoL was maintained, while their parents reported improvements in their child's "Physical Health". Trends in psychologic/social domains were less consistent across age groups; however, patients across age groups reported improvements in "Feeling". Adults reported improvements in participating in work/school activities by the end of the trial. These findings highlight the potential benefits beyond physical health of N8-GP when administered prophylactically.
Santagostino et al 18 investigated the HRQoL of patients with severe hemophilia A treated with turoctocog alfa for a mean duration of 6 months among patients aged 12-65 years (guardian™1) or for a mean duration of 4.5 months among 
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Kearney et al patients aged 0-11 years (guardian™3). The patients who participated in these trials had similar overall HRQoL, as measured by the total Haemo-QoL/Haem-A-QoL score at baseline, compared to patients in the pathfinder™ trials at baseline. Both the guardian™ and the pathfinder™ trials showed similar trends of improvements or maintained overall HRQoL during the course of their respective trials for all age groups. The only exception was that children aged 4-7 years and their parents in the guardian™3 trial reported no change in the overall HRQoL during the trial, while both children and their parents reported substantial improvement in the overall HRQoL in the pathfinder™5 trial. In the guardian™ and pathfinder™ trials, patients entered their respective trial with a good HRQoL, which leaves little room for improvement in HRQoL during the duration of the trial. In the A-LONG study in which adult hemophilia A patients were treated with another EHL product, a recombinant factor VIII FC fusion protein on a prophylactic (weekly prophylaxis or individualized prophylaxis) or episodic (as needed) regimen, significant HRQoL changes between baseline and 28 weeks follow-up were found only for the individualized prophylaxis arm in the Haem-A-QoL "Physical Health" domain and the "Total Score". 19 In contrast in the pathfinder™2 trial, significant mean HRQoL changes between baseline and the end of the main phase were seen in the prophylaxis arm for the Haem-A-QoL domains "Physical Health", "Feeling", "View", "Work", and the "Total Score".
Parents of children and adolescents as well as adult patients reported high levels of TS at baseline, indicating high satisfaction with treatment received prior to entering the trial. Similarly, they showed high levels of TS with N8-GP, as measured by the Hemo-Sat scores at the end of the main phase. When examining the change in Hemo-Sat scores, the TS levels were either comparable between N8-GP and the previous treatment or higher for N8-GP, suggesting potentially higher TS with the new drug. However, caution should be applied when interpreting these findings, as previous works have found that the expectation of treatment received prior to entering a trial may not match up with the expectation of the treatment received during the trial. 20, 21 The claim of increased TS for N8-GP, however, can be supported with the low median ABR reported for pathfinder™5 and for pathfinder™2. 12, 13 Several limitations of the analysis should be highlighted. The study of HRQoL within the pathfinder™ clinical trials is hindered by the lack of randomization and blinding which results in the loss of a comparator arm and potential bias based on preconceived ideas of efficacy. Small sample sizes and missing data are also problematic, especially in the younger age groups in the pathfinder™ trials.
It has been previously shown that age is a predictor of HRQoL among individuals with severe hemophilia, where older individuals are more likely to report poorer HRQoL on the generic 36-Item Short Form Survey (SF-36) and European Quality of Life 5 dimensions (EQ-5D). 22, 23 In this study, HRQoL was analyzed separately for each age group, as individual's experiences vary dependent on age. This was reflected by the multiple age-specific versions of the Haemo-QoL/ Haem-A-QoL. The association between change in HRQoL and change in ABR could not be completed due to the absence of baseline ABR data. Finally, the analyses of HRQoL are based on a relatively short or limited exposure with N8-GP (26 weeks for pathfinder™5 and up to 76 weeks for pathfinder™2).
Despite these challenges, there is limited knowledge on HRQoL among patients with hemophilia A, especially 
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Kearney et al in the youngest subgroups. Therefore, even with a limited sample size, this study contributes to the understanding of the HRQoL of hemophilia patients, specifically focusing on the potential differences in HRQoL in patients receiving EHL FVIII replacement therapy. Further longitudinal data may be obtained based on the extension phase of these trials to understand the long-term usage of EHL FVIII replacement therapies. As newer EHL therapies entering the market aim to reduce the number of injections and to increase trough levels, future analyses can examine if the frequency of dosing (bi-weekly vs every 4 days) or trough level impact HRQoL.
Conclusion
Treatment with N8-GP resulted in a good disease-specific HRQoL of children, adolescents, and adults with severe hemophilia A. While most patients entered their respective trials with a good disease-specific HRQoL, the HRQoL of patients was either maintained or further improved when treated with N8-GP. Adults and parents of children and adolescents further reported high levels of treatment satisfaction with N8-GP.
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